alcanza: brentuximab vedotin improves orr and pfs in ctcl
Published 2 years ago • 116 plays • Length 0:46Download video MP4
Download video MP3
Similar videos
-
2:46
alcanza: brentuximab vedotin for ctcl
-
3:48
phase ii study of brentuximab vedotin chp in patients with ptcl with less than 10% cd30 expression
-
1:04
updates on the use of brentuximab vedotin in later-stage hl
-
3:09
real-world efficacy of brentuximab vedotin as consolidation therapy in patients with hl
-
1:41
swog s1826: nivolumab avd vs brentuximab vedotin avd for advanced stage hodgkin lymphoma
-
1:11
brentuximab vedotin: current status and future considerations for this agent in hl treatment
-
3:23
brentuximab vedotin, nivolumab, doxorubicin & dacarbazine for early stage classical hodgkin lymphoma
-
4:22
brentuximab vedotin-nivolumab alone and then with r-chp as frontline therapy for pmbcl
-
2:39
advancements in bispecific and trispecific antibodies for the treatment of lymphoma
-
11:55
progress report v - bulcsú bencze
-
14:37
progress report v - ruben borbély
-
1:08
nivolumab and brentuximab vedotin with or without bendamustine for r/r hodgkin lymphoma
-
1:27
treatment options for patients with hodgkin lymphoma who progress after brentuximab vedotin
-
1:14
brentuximab vedotin combined with nivolumab for hodgkin lymphoma
-
1:55
the real-world efficacy of brentuximab vedotin consolidation post-autosct in r/r hl
-
2:05
updates on frontline brentuximab vedotin for peripheral t-cell lymphoma
-
2:36
brentuximab vedotin versus pembrolizumab in r/r classical hodgkin lymphoma
-
2:56
continuous btki therapy in cll: are time-limited combination therapies more beneficial?
-
1:42
brentuximab vedotin after autosct in pediatric patients with r/r hodgkin lymphoma
-
3:37
progress in the categorization and treatment of lr-mds
-
3:21
brentuximab vedotin nivolumab in lymphoma
-
3:16
mariposa-2: second interim os of amivantamab and chemotherapy in egfr-m nsclc